Navigation Links
Phase 3 Cystic Fibrosis Trial Results Presented at European Conference
Date:6/15/2009

offatt@pharmaxis.com.au>felicity.moffatt@pharmaxis.com.au United States: Brandon Lewis Trout Group Tel: +1-646-378-2915 Email: blewis@troutgroup.com
'/>"/>
SOURCE Pharmaxis Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
6. Phase III Trial Finds Pharmaxis Bronchitol Effective
7. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
8. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
9. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
10. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
11. Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 23, 2013 Venaxis, Inc. ... company focused on obtaining FDA clearance and commercializing its ... announced the pricing of an underwritten public offering of ... to purchase 3,500,000 shares of its common stock at ... combined public offering price of $1.25 per share and ...
(Date:5/23/2013)... 23, 2013 Patheon Inc ., ... to the global pharmaceutical industry, will host a complimentary ... to Testing” on Tuesday, June 4, 2013 at 11 ... are required to comply with regulations for cleaning validation. ... limited scientific underpinning and little evaluation of risk. ...
(Date:5/23/2013)... MA (PRWEB) May 23, 2013 ... inch wide and provide 15 mm travel range ... The small dimensions make these new positioners ... confined spaces. A vacuum rated version is also ... Drawings, specifications and datasheets can be found at: ...
(Date:5/23/2013)... 2013 BioTrends Research Group, one of ... specialized biopharmaceutical issues, finds that, unaided, one in ... reported that in the past six months, they ... in anticipation of the next generation of HCV ... only 6 percent reported that they had begun ...
Breaking Biology Technology:Venaxis Announces Pricing of Offering of Common Stock and Warrants 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 3Patheon to Present on “Cleaning Validation: Science, Risk and Novel Approaches to Testing” 2Precision Positioning System Uses Miniaturezed Piezo Linear Motor: LPS-24 Linear Stage by PI 2The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 2The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 3
... ... working in continuous flow chemistry processing, will deal with the application of the ReactIR flow ... of over 670 publications has been recognized with several prestigious prizes and awards, including most ... ...
... Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced that ... Healthcare Conference on Wednesday, November 11, at 9:30 a.m. ... may access a live webcast of the presentation on ... It is recommended that listeners log on 15 minutes ...
... 4 Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ... and webcast discussing the Company,s 2009 third quarter results on ... Flavin, Ph.D., Chairman & Chief Executive Officer, as well as ... update on the Company. A press release reporting the 2009 ...
Cached Biology Technology:Professor Steven Ley of University of Cambridge will Present Free Webinar, 'Application of the ReactIR Flow Cell to Continuous Processing Technology' 2Professor Steven Ley of University of Cambridge will Present Free Webinar, 'Application of the ReactIR Flow Cell to Continuous Processing Technology' 3Advanced Life Sciences to Host 2009 Third Quarter Financial Results Conference Call and Webcast 2
(Date:5/23/2013)... , Automated conserved noncoding sequence (CNS) ... among grasses , Within the genome of each ... undergo little change in position and sequence over millions ... Some of these evolutionarily stable sequences, so-called conserved noncoding ... other genes or the condensation of chromosomes, but the ...
(Date:5/23/2013)... of Public Health at Emory University, along with ... received a $4 million grant over four years ... (Health and Exposome Research Center: Understanding Lifetime Exposures). ... awarded in the United States. , The ... of Environmental Health Sciences (NIEHS) of the National ...
(Date:5/23/2013)... cancer patients unnecessarily undergo surgery or harsh treatments ... slow-growing and aggressive forms of the disease. Researchers ... Medical Institutes are developing technology that allows patients ... relatively mild treatments or take drastic measures. , ... an associate professor of biomedical engineering at Case ...
Breaking Biology News(10 mins):Frontiers news briefs: May 23 2Frontiers news briefs: May 23 3Emory, Georgia Tech receive first human exposome center grant in US 2Emory, Georgia Tech receive first human exposome center grant in US 3Using big data to identify prostate cancers and best treatments 2Using big data to identify prostate cancers and best treatments 3
... of Allergy and Infectious Diseases (NIAID), part of ... a promising drug candidate attacks the bacterium that ... Proceedings of the National Academy of Sciences, the ... PA-824, which targets Mycobacterium tuberculosis (M. tb). ...
... Scientists at New York University School of Medicine report in ... that turns on the production of myelin, the fatty insulation ... the nervous system. The study, published in the September 1, ... avenue for treating nervous system diseases such as multiple sclerosis, ...
... could have a damaging effect on plant life, according ... Jersey Institute of Technology (NJIT). , The report, ... that nanoparticles of alumina (aluminum oxide) slowed the growth ... cucumber, cabbage, carrot and soybean. Alumina nanoparticles are commonly ...
Cached Biology News:NIAID researchers show how promising TB drug works 2NIAID researchers show how promising TB drug works 3Scientists discover the molecular switch for nerve cells' insulating jelly rolls 2NJIT study shows nanoparticles could damage plant life 2
... Genome Amplification Kit utilizes a proprietary ... genomic DNA and conversion of the ... molecules flanked by universal priming sites. ... of the library molecules using universal ...
...
From formula-fed bovine calves Sterile, Cell culture tested...
Collected at a certified USDA establishment located within the United States. All final processing is done by Quad Five employees....
Biology Products: